

## DAFTAR PUSTAKA

1. Sejati A, Sofiana L. Faktor-Faktor Terjadinya Tuberkulosis. *Jurnal Kesehatan Masyarakat*. 2015;10(2):122.
2. Rafflesia U. Model Penyebaran Penyakit Tuberkulosis (TBC). 2014;10(Vol 10, No 2 (2014): Juli 2014):983–6.  
diunduh dari: <http://ejournal.unib.ac.id/index.php/gradien/article/view/225>  
diunduh pada: 5 juli 2019.
3. Irianti, Kuswandi, Yasin NM, Kusumaningtyas RA. *Mengenal Anti-Tuberkulosis*. Yogyakarta; 2016. 151 p.
4. Kementerian Kesehatan Republik Indonesia. *Multi Drug Resistant*. 2019.  
diunduh dari: [www.tbindonesia.or.id/page/view](http://www.tbindonesia.or.id/page/view)
5. *Tuberkulosis*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI; 2015. p. 1–6.
6. Ika. Kasus TB Kebal Obat di Indonesia Mencapai 8 . 900 Orang per Tahun. *Universitas Gadjah Mada*. 2016;(November).
7. Kementerian Kesehatan RI. *Rencana Aksi Nasional Programmatic Management of Drug resistance Tuberculosis*. Pengendalian Tuberkulosis Indonesia: 2011-2014.
8. Erlina Burhan. Peran ISTC Dalam Pencegahan MDR. *Jurnal Tuberkulosis Indonesia*. 2010;7:1–12.
9. *Everything You Should Know About Drug-Resistant TB*. Departement Healt South Africa. :2.

10. Wiratmoko M dr. Tuberkulosis Multi Drug Resistant (Tb-Mdr). Universitas Muhammadiyah Jakarta. 2015;1–8.  
diunduh dari : [http://www.fkkumj.ac.id/berita-tuberkulosis-multi-drug resis](http://www.fkkumj.ac.id/berita-tuberkulosis-multi-drug-resis)
11. Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Manajemen dan Tatalaksana TB Anak. 2016. p. 49–56.
12. Vasconcelos J alves de araujo filho. AC. Multidrug-resistant tuberculosis: Case Reports Study In a Central State of Brazil. Brazilian Journal Infectious Disea. 2018;12(1):2–7.
13. Pennan M. Barry, Adithya Cattamanchi, Lisa Chen, Amit S. Chitnis, Charles L. Daley JMF. Drug-Resistant Tuberculosis. Curry International Tuberculosis Centreal. 2016;3:1–89.
14. World Health Organization. MDR TB/RR TB Factsheet TB 2017. 1–2.  
diunduhdari :[http://www.who.int/tb/publications/2011/factsheet\\_tb\\_2011.pdf](http://www.who.int/tb/publications/2011/factsheet_tb_2011.pdf)
15. World Health Organization. Tuberculosis ( MDR-TB ). 2018;1–2.
16. Widiastuti EN, Subronto YW, Promono D. Determinan Kejadian Multi-drug Resistant Tuberculosis di RSUP Dr. Sardjito. Berita Kedokteran Masyarakat. 2017;33(7):328.
17. Perhimpunan Dokter Paru Indonesia. Klasifikasi Tuberkulosis. Pedoman Diagnosis Penatalaksanaan di Indonesia. :11.
18. Kementerian Kesehatan RI Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. Petunjuk Teknis Manajemen Terpadu Pengendalian Resistan Obat. Jakarta; 2014. 15–26 p.
19. Morier D. Mechanism Of Resistance. Antibiotic Resistant. 2017;53(9).

20. Alexander S PYM , Brigitter Saint Joanis STC. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. *Infection Immun* 70(9):4955–60.
21. Retnoningrum DS, Kembaren RF. Mekanisme Tingkat Molekul Resistensi Terhadap OAT INH dan RIF. Mekanisme Tingkat Molekul Resistensi terhadap Beberapa Obat pada Mycobacterium Tuberculosis. *XXIX(3)*:92–5.
22. Johnson Rabia, Streicher Elizabeth LG. Molecular Mechanisms of Drugs Resistance. *Drug Resist Mycobacterium Tuberculosis*. 8:99–101.
23. Ikhsan M. Metode, Teknik PCR (Polymerase Chain Reaction). Deteksi Mycobacterium Tuberculosis dan Resistensi dengan Teknik PCR (Polymerase Chain React dan GeneXpert MTB/RIF) . 2016;15.
24. Rivani E, Sabrina T, Patricia VP. Perbandingan uji diagnostik GeneXpert MTB/RIF untuk mendeteksi resistensi rifampicin Mycobacterium tuberculosis pada pasien Tb paru di RSUP dr. Moh. Hoesin Palembang. *Jurnal Kedokteran dan Kesehatan Publikasi Ilmu Fakultas Kedokteran Universitas Sriwijaya*. 2019;6(1):23–8.
25. Schinazi RF, Kohler JJ, Kim B. Reverse Transcription. *Brenner's Encycl Genet*. 2013;2:224–224.
26. Kemenkes RI. Pemantauan dan Hasil Pengobatan. *Pedoman Nasional Pengendali Tuberkolosis*. :32.
27. Smith SE, Pratt R, Trieu L, Barry PM, Thai DT, Ahuja SD, et al. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014. *Clinical Infection Disease*. 2017;65(9):1437–43.

28. Karan Madan, Anant Mohan, Ritesh Agarwal, Vijay Hadda, Gopi C Khilnani, Randeep Guleria. A survey of flexible bronchoscopy practices in India: The Indian bronchoscopy survey (2017). *Lung India*. 2018;35(2):98–107.
29. MDR-TB. centers Disease Preventive Control Tb Disease. 2017;
30. Schaaf HS. Prevention and management of MDR in children. *Desmon Tutu TB Centre*. 1953;(5):18–21.
31. Aminah S., Suharsono, Sutrisna E. Evaluasi Penggunaan Obat Antituberkulosis Pada Pasien Tuberculosis Multi Drug Resistant Di Rumah Sakit X Periode Januari-Juni 2013. Naskah Publikasi. 2014;
32. Putri VA, Yovi IY, Fauzia D. Profil Pasien Tuberculosis Multidrug Resistance (Tb-Mdr) Di Poliklinik Tb-Mdr RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014. 2015;2(2):1–17.
33. Sri MM, Nawas; A, Soetoyo; DK. Pengamatan Pasien Tuberculosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. *Jurnal Respirologi Indonesia*. 2010;30(2):1 of 13.
34. Reviono F, Kusnanto P, Eko V, Pakiding H, Nurwidiasih D, et al. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberculosis. *Pulmonologi dan Ilmu Kedokteran Respirasi* . 2014;46(4):189–96.
35. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. 2014. 464 p.
36. Bhatt CP KB. Side Effect Associated With Drugs Used In Treatment Of Multi Drug Resistant Tuberculosis and Treatment Related Factors Of Multi Drug

Resistant Tuberculosis Patients In Kathmandi Calley. Khatmandu Medical College Public Limited, Sinamangal, Kathmandu, Nepal. 2017;(1):1–6.

37. Tamam Anugrah Tamsil, Arifin Nawas DKS. Pengobatan Multidrugs Resistant Tuberculosis ( MDR-TB ) dengan Paduan Jangka Pendek. Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, Fakultas Kedokteran Universitas Indonesia RS Persahabatan Jakarta. 2015;(April 2014).